ANIP : Insider Transactions for ANI Pharmaceuticals Inc | J3SG

Sign in:	Email	Password save:

		Company Reports
Find Symbol

Recent: Companies Filers Institutions

Membership is free, please Sign Up.

My Recent Searches

Help

Roster

Institutions

Add To Portfolo/Alerts

Get Insiders for :

ANI Pharmaceuticals Inc (ANIP)

$67.11

0.59 (0.89%) as of 4:30 Thu 5/2

Download

Exchange:

Nasdaq National Market

Security Type:

Common

Shares Out:

20,430,000

Market Cap:

1.37(B)

Last Volume:

2,387,520

Avg Vol:

2,380,857

52 Week Range:

$37.29 - $69.69

Level I Sector:

Health Care

Level II Sector:

Drugs

Level III Sector:

Biotechnology

Member Indexes:

AMEX COMPOSITE

Rankings:

Insider 3 Months : -

Insider 6 Months : -

Insider 3/6 Months : -

Guru Rank Number : -

Guru Rank Value : -

Guru Occurances : -


6 Months 1 Year 2 Year


Company Profile ANI Pharmaceuticals is a bio-pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Co.'s products include: Candesartan Hydrochlorothiazide, Fenofibrate, Fluvoxamine, Hydrocortisone Enema, Lithium Carbonate ER, Mesalamine, Propranolol ER, Terbutaline, and Vancomycin.

D/I:

D is for direct shares.
I is for indirect shares.

D/I refers to the Direct or Indirect shares traded vs. held.

Forms:

A Form 4 is a form filed by an insider to indicate a change in ownership.

A Form 3 is a form filed by an insider to indicate an initial ownership of a security.

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.

Actions:

B	Buy
S	Sell
OE	Option Exercised
A	Acquired
D	Disposed
AB	Automatic Buy
AS	Automatic Sell
IO	Initial Ownership

Download:

Download only Transactions Forms. (Default)

Download only Summary Infomation.

Download both Transactions and Summary Data

Summary (Direct Transactions Only)	3 Months	6 Months	12 Months	24 Months
Total Shares Bought	0	0	0	0
Total Buy Value	$0	$0	$0	$0
Total People Bought	0	0	0	0
Total Buy Transactions	0	0	0	0
Total Shares Sold	230,132	422,694	1,171,108	1,389,174
Total Sell Value	$15,188,297	$25,482,465	$68,628,084	$77,001,153
Total People Sold	8	9	11	11
Total Sell Transactions	20	41	78	81
End Date	2024-02-01	2023-10-31	2023-05-02	2022-05-02

Adjust Filter Settings

Records found: 399

Page 3 of 16

Filer's Name

Relation Title

Off-Dir-10%

D/I

Rank

3m +/-

Form

SR. VP, GENERAL COUNSEL & SEC.

• – –

2024-02-13

4

AS

$56.04

$14,010

D/D

(250)

36,799

19%

Shanmugam Muthusamy

HEAD OF R&D, COO-NOVITIUM OPS

• • –

2024-01-23

4

AS

$56.44

$846,600

I/I

(15,000)

882,620

15%

Shanmugam Muthusamy

HEAD OF R&D, COO-NOVITIUM OPS

• • –

2024-01-22

4

AS

$55.95

$318,467

I/I

(5,692)

897,620

16%

Shanmugam Muthusamy

HEAD OF R&D, COO-NOVITIUM OPS

• • –

2024-01-19

4

AS

$55.57

$251,399

I/I

(4,524)

903,312

18%

Shanmugam Muthusamy

HEAD OF R&D, COO-NOVITIUM OPS

• • –

2024-01-18

4

AS

$55.30

$541,055

I/I

(9,784)

907,836

18%

Shanmugam Muthusamy

HEAD OF R&D, COO-NOVITIUM OPS

• • –

2024-01-17

4

AS

$55.11

$551,100

I/I

(10,000)

917,620

18%

Shanmugam Muthusamy

HEAD OF R&D, COO-NOVITIUM OPS

• • –

2024-01-16

4

AS

$55.63

$278,150

I/I

(5,000)

927,620

18%

SR. VP, GENERAL COUNSEL & SEC.

• – –

2024-01-12

4

AS

$56.43

$14,108

D/D

(250)

37,049

15%

Shanmugam Muthusamy

HEAD OF R&D, COO-NOVITIUM OPS

• • –

2023-12-19

4

AS

$52.65

$1,316,250

I/I

(25,000)

932,620

24%

Shanmugam Muthusamy

HEAD OF R&D, COO-NOVITIUM OPS

• • –

2023-12-18

4

AS

$52.44

$683,083

I/I

(13,026)

957,620

25%

Shanmugam Muthusamy

HEAD OF R&D, COO-NOVITIUM OPS

• • –

2023-12-15

4

AS

$52.44

$627,917

I/I

(11,974)

970,646

24%

SR. VP, GENERAL COUNSEL & SEC.

• – –

2023-12-11

4

AS

$49.21

$12,303

D/D

(250)

37,299

31%

Shanmugam Muthusamy

HEAD OF R&D, COO-NOVITIUM OPS

• • –

2023-11-17

4

AS

$51.00

$663,000

I/I

(13,000)

982,620

32%

Shanmugam Muthusamy

HEAD OF R&D, COO-NOVITIUM OPS

• • –

2023-11-16

4/A

AS

$51.66

$333,104

I/I

(6,448)

995,620

-

Shanmugam Muthusamy

HEAD OF R&D, COO-NOVITIUM OPS

• • –

2023-11-16

4

AS

$51.66

$333,104

I/I

(6,448)

996,430

35%

Shanmugam Muthusamy

HEAD OF R&D, COO-NOVITIUM OPS

• • –

2023-11-15

4/A

AS

$53.64

$410,185

I/I

(7,647)

1,002,068

-

SVP, CHIEF HR OFFICER

• – –

2023-11-15

4

S

$53.81

$141,090

D/D

(2,622)

32,587

-33%

Shanmugam Muthusamy

HEAD OF R&D, COO-NOVITIUM OPS

• • –

2023-11-15

4

AS

$53.64

$410,185

I/I

(7,647)

1,002,878

33%

Shanmugam Muthusamy

HEAD OF R&D, COO-NOVITIUM OPS

• • –

2023-11-14

4/A

AS

$53.17

$1,217,859

I/I

(22,905)

1,009,715

-

Shanmugam Muthusamy

HEAD OF R&D, COO-NOVITIUM OPS

• • –

2023-11-14

4

AS

$53.17

$1,174,791

I/I

(22,095)

1,010,525

31%

SR. VP, GENERAL COUNSEL & SEC.

• – –

2023-11-13

4

AS

$52.03

$13,008

D/D

(250)

37,549

35%

Mutz Christopher

HEAD OF RARE DISEASE

• – –

2023-11-10

4

S

$52.47

$157,410

D/D

(3,000)

63,607

-33%

Shanmugam Muthusamy

HEAD OF R&D, COO-NOVITIUM OPS

• • –

2023-10-19

4

AS

$57.06

$570,600

I/I

(10,000)

1,032,620

18%

Shanmugam Muthusamy

HEAD OF R&D, COO-NOVITIUM OPS

• • –

2023-10-18

4

AS

$57.78

$360,663

I/I

(6,242)

1,042,620

5%

Shanmugam Muthusamy

HEAD OF R&D, COO-NOVITIUM OPS

• • –

2023-10-17

4

AS

$58.53

$512,606

I/I

(8,758)

1,048,862

3%

399 Records found	1 2 3 4 5 6 7 8 9 Next	Page 3 of 16

	Transaction Code Key:				Ownership Code Key
	B	- Buy	AB	- Automatic Buy	D	- Direct Ownership
	S	- Sell	AS	- Automatic Sell	I	- Indirect Ownership
	OE	- Options Exercised	A	- Acquired
	IO	- Initital Ownership	D	- Disposed

Copyright © 2024 j3sg.com | Disclaimer & Terms of use Products & Service About Us Contact Us

Summary:

Chart:

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.